Skip to main content
MRK
NYSE Life Sciences

默克的Welireg-Lenvima联合疗法降低30%的癌症进展风险；FDA接受NDAs

feedReported by Reuters
Sentiment info
Positive
Importance info
8
Price
$123.31
Mkt Cap
$306.132B
52W Low
$73.31
52W High
$125.14
Market data snapshot near publication time

summarizeSummary

默克宣布，其Welireg加上Lenvima的联合治疗方案与卡博替尼（cabozantinib）相比，在某些以前接受过治疗的晚期肾细胞癌（RCC）患者中，降低了30%的疾病进展或死亡风险。FDA还接受了两份关于该联合治疗的补充新药申请（sNDAs）进行审查。这一积极的临床和监管更新是在2月27日有关默克Keytruda联合治疗的强劲消息之后，这表明了公司具有强大的肿瘤学产品线。这一数据加强了默克在Keytruda之外的肿瘤学产品组合，并提供了一个潜在的新增长动力，这可能有助于抵消公司最近的10-K文件中强调的未来来自Keytruda的收入压力。投资者将监测FDA的审查过程和潜在的审批时间表对于Welireg加上Lenvima的联合治疗。

在该公告发布时，MRK的交易价格为$123.31，交易所为NYSE，所属行业为Life Sciences，市值约为$3061.3亿。 52周交易区间为$73.31至$125.14。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Reuters。

show_chartPrice Chart

Share this article

Copied!

feed MRK - Latest Insights

MRK
Apr 24, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Merck Clears Key Antitrust Hurdle for Terns Pharmaceuticals Acquisition
Sentiment: Positive
View Wiseek Article
MRK
Apr 21, 2026, 11:50 AM EDT
Source: Reuters
Importance Score:
8
US FDA Approves Merck's New Combination HIV Treatment
Sentiment: Positive
View Wiseek Article
MRK
Apr 21, 2026, 6:51 AM EDT
Source: Reuters
Importance Score:
8
Merck-Eisai Cancer Therapy Fails Late-Stage Study Goals
Sentiment: Negative
View Wiseek Article
MRK
Apr 20, 2026, 7:29 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
FDA Grants Priority Review to Merck, Pfizer Bladder Cancer Drug Combo
Sentiment: Positive
View Wiseek Article
MRK
Apr 13, 2026, 4:06 PM EDT
Source: Wiseek News
Importance Score:
8
Merck Actively Pursues Acquisitions to Bolster Pipeline Ahead of Keytruda Patent Expiration
Sentiment: Positive
View Wiseek Article
MRK
Apr 08, 2026, 4:25 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Merck Projects Over $70B Pipeline Opportunity, Details Executive Changes and Annual Meeting Proposals
Sentiment: Positive
View Wiseek Article
MRK
Mar 30, 2026, 4:04 PM EDT
Source: Wiseek News
Importance Score:
9
Merck's Oral PCSK9 Inhibitor Enlicitide Cuts LDL-C 64.6% in Phase 3, Outperforming Competitors
Sentiment: Positive
View Wiseek Article
MRK
Mar 30, 2026, 11:48 AM EDT
Source: Reuters
Importance Score:
9
Merck's Oral PCSK9 Inhibitor Enlicitide Decanoate Slashes LDL-C by 64.6%, Earns FDA Priority Voucher
Sentiment: Positive
View Wiseek Article
MRK
Mar 29, 2026, 11:49 AM EDT
Source: Reuters
Importance Score:
8
Merck's Winrevair Hits Phase 2 Endpoint, Advancing to Registrational Phase 3 for Pulmonary Hypertension
Sentiment: Positive
View Wiseek Article
MRK
Mar 25, 2026, 6:45 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Merck Acquires Terns Pharma, Bolstering Hematology Pipeline with Novel CML Candidate TERN-701
Sentiment: Positive
View Wiseek Article